 |
|
Cost-effectiveness of Alternative Triage Strategies for Atypical Squamous Cells of Undetermined Significance
Jane J. Kim, MS;
Thomas C. Wright, MD;
Sue J. Goldie, MD,MPH
JAMA. 2002;287:2382-2390.
ABSTRACT
| |
Context Every year approximately 2 million US women are diagnosed as having a cervical cytological result of atypical squamous cells of undetermined significance (ASC-US).
Objective To determine the most efficient and cost-effective management strategy for women in the United States diagnosed as having ASC-US.
Design and Setting Cost-effectiveness analysis of data from clinical trials, prospective studies, and other published literature. A computer-based model was used to compare 4 management strategies for a cytological result of ASC-US: immediate colposcopy; human papillomavirus (HPV) triage, which includes colposcopy if high-risk HPV types are detected; repeat cytology, which includes follow-up cytology at 6 and 12 months and referral for colposcopy if a repeat abnormal result occurs; and reclassifying ASC-US as normal in which a cytological result of ASC-US is ignored. Reflex HPV DNA testing uses either residual liquid-based cytological specimens or samples co-collected at the time of the initial screening for conventional cytology. Another method, referred to as the 2-visit HPV DNA triage, requires a woman with an ASC-US result to return within 1 month to provide another speciman sample.
Main Outcome Measures Years of life saved (YLS), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.
Results The least costly strategy for biennial screening was to reclassify ASC-US as normal, resulting in a reduction in total cancer incidence of 75% for conventional cytology and 84% for liquid-based cytology compared with no screening. The next least costly strategy was HPV DNA testing resulting in a reduction in total cancer incidence of 86% for conventional cytology and 90% for liquid-based cytology, followed by immediate colposcopy with a reduction of 87% and 91%, respectively. Compared with reflex HPV DNA testing, a strategy of repeat cervical cytology or delayed HPV testing costs more but is less effective. When all strategies were compared simultaneously, varying frequency and type of cytological test, biennial (vs every 3 years) liquid-based cytology with reflex HPV testing had a cost of $174 200 per YLS. In a similar comparison, liquid-based cytology with reflex HPV testing conducted every 3 years (vs every 5 years) had a cost of $59 600 per YLS and was more effective and less costly than a strategy of conventional cytology incorporating repeat cytology or immediate colposcopy conducted biennially.
Conclusion Reflex HPV DNA testing provides the same or greater life expectancy benefits and is more cost-effective than other management strategies for women diagnosed as having ASC-US.
INTRODUCTION
In the United States, cytological screening has reduced the incidence of invasive cervical cancer, but as a result of screening, many women are diagnosed as having equivocal cytological abnormalities (eg, atypical squamous cells, herein referred to as ASC).1 The management of an ASC result is controversial, and clinical practice patterns range from performing immediate colposcopy to repeating cervical cytology at specified intervals.2 Clinicians who prefer immediate colposcopy argue that some women with ASC have cervical intraepithelial neoplasia grade 2-3 (CIN 2-3) or invasive cancer, and in fact, a substantial proportion of all biopsy-confirmed CIN 2-3 is identified in women with an ASC result.3 Clinicians who prefer to use repeat cytology argue that most women have either no lesion or CIN grade 1, which is likely to regress in the absence of any treatment. A third option is DNA testing for high-risk types of human papillomavirus (HPV) and performing colposcopy only in women with positive test results. This strategy is increasingly adopted in the United States because HPV DNA testing appears to be more sensitive than a single repeat cervical cytology for identifying women with ASC who have CIN 2-3.4-8
Determining the most effective and efficient management approach for ASC in a given setting requires a formal analysis of costs and benefits. To contribute information prior to the deliberations of professional organizations developing national guidelines for the optimal management of ASC, we conducted a comprehensive cost-effectiveness analysis comparing different strategies.
METHODS
Natural History Model
We modified a previously developed computer-based mathematical model,9-11 which simulates the natural history of cervical carcinogenesis using a sequence of monthly transitions among health states (Figure 1). HPV infection is defined as either detectable or undetectable to accurately represent the proportion of CIN 1 and CIN 2-3 that would be detectable in a clinical practice setting. This structure was chosen to permit calibration to cross-sectional data on the distribution of detectable HPV DNA within low-grade squamous intraepithelial lesions (LSILs) and high-grade squamous intraepithelial lesions (HSILs). Biopsy-confirmed cervical disease is defined as either CIN 1 or CIN 2-3, whereas cytological results are classified as ASC, LSIL, or HSIL.12 Invasive cervical cancer is stratified according to the cancer staging system of the National Cancer Institute's Surveillance, Epidemiology, and End-Results Program (local, regional, and distant cancer).13
|
|
|
|
Figure 1. Natural History Model
Health states were defined using 4 categories of cervical health (normal, infection with human papillomavirus [HPV], grade of cervical intraepithelial neoplasia [CIN], and stage of invasive cancer). See "Methods" for details.
|
|
|
For our analyses, a hypothetical cohort of adolescent girls were entered into the model at age 13 years. They have never had sex, are free of disease, but at each month face an age-dependent risk of acquiring HPV. Females with detectable high-risk types of HPV (defined as HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 61 detected using a sensitive molecular assay) have a greater risk of CIN 2-3 and invasive cancer than those with undetectable HPV.14-16 Women with high-risk HPV types, which are not detected using a single test, and women with low-risk HPV types are considered to be in an undetectable dimensional health state. Women infected with high-risk HPV types, as well as some women with false-positive test results (eg, low-risk types of HPV), are considered to be in a detectable dimensional health state. Women with HPV infection or established cervical lesions can regress to normal, progress to HSILs or cervical cancer, or stay the same. Unique health states are defined to distinguish women with previously abnormal screening results, prior treatment for CIN, and detected cervical disease (through symptoms or screening). Women may die at any age due to a cervical cancer-related illness.
Strategies
We discuss 3 main strategies to manage ASC: (1) immediate colposcopy (all women receive colposcopy); (2) HPV DNA triage (colposcopy only if high-risk HPV types are detected); (3) repeat cytology (follow-up cytology at 6 and 12 months and referral for colposcopy for a repeat cytological result of ASC, LSIL, HSIL, or cancer). We also evaluate the implications of using a higher threshold on repeat cytology (eg, HSIL) for referral to colposcopy, and of a fourth strategy in which ASC is reclassified as normal (ie, a cytological result of ASC is ignored).
We used the new 2001 Bethesda System,17 which subcategorizes ASC into atypical squamous cells of undetermined significance (ASC-US) and atypical squamous cells that cannot exclude HSIL (ASC-H) for our base case. The ASC-H category constitutes approximately 5% of all ASC, but includes women at greatest risk for CIN 2-3.18-19 We assumed that all women with ASC-H receive colposcopy, although alternative options are evaluated in separate analyses. Since the majority of published literature has not distinguished between ASC-H and ASC-US, we also conducted analyses in which ASC was not stratified.
Testing of HPV DNA could be incorporated into the management of women with ASC-US in several ways. One is reflex HPV DNA testing using either the residual in a liquid-based cytological specimen or, in the case of conventional cytology, a sample co-collected at the time of the initial screening. Both approaches eliminate the need for a second examination to collect a sample. Another way to incorporate HPV DNA testing with conventional cytology is to have women with ASC-US return for a second visit within 1 month to collect a sample for HPV DNA testing (referred to as 2-visit HPV DNA triage). In all HPV DNA testing strategies, women who receive a positive test result for high-risk types of HPV are referred to colposcopy, while all others continue with routine cytological screening.
For the base case we assume: (1) general screening begins at age 18 years and occurs every 2 years in the absence of a cytological abnormality; (2) colposcopy is performed for all cytological results of SIL but treatment is reserved for biopsy-confirmed CIN 2-3; (3) women who are treated for CIN 2-3, or have biopsy-confirmed CIN 1 return for a repeat cytological test every year; (4) women with ASC-US in whom no CIN is identified at colposcopy return to routine screening; (5) compliance with primary screening and follow-up is 100%; and (6) disease status is confirmed by colposcopy and biopsy. The implications of alternative assumptions were evaluated in sensitivity analyses. We compared the different options within each possible screening frequency for both liquid-based and conventional cytology separately. Next, to identify the most efficient screening options not conditional on any particular screening interval or cytological technique, we simultaneously compared ASC-US management options, screening frequencies, and type of cytology.
We adopted a societal perspective and followed the recommendations of the Panel on Cost-effectiveness in Health and Medicine.20 Costs are expressed in 2000 US dollars and clinical benefits are expressed as years of life saved and quality-adjusted life-years (QALYs) gained. Future costs and life-years are discounted at an annual rate of 3%. The performance of alternative screening strategies is measured using the incremental cost-effectiveness ratio, defined as the additional cost of a specific screening strategy, divided by its additional clinical benefit, compared with the next most expensive strategy.
Clinical Data
Selected data used for the base case are summarized in Table 1. 9-11,21-61 To check the face validity of our model, we projected the age-specific prevalence of HPV, CIN, and invasive cervical cancer and compared these outputs with population-based data not used to create the model.62-72 Model corroboration was assessed by comparing the projected lifetime risk of invasive cervical cancer with estimates from other published analytic models.11, 27-28,73
|
|
|
|
Table 1. Model Variables: Baseline Values and Ranges Used in Sensitivity and Specificity Analyses*
|
|
|
Natural History
Our model requires parameters for the natural history of cervical disease conditional on a woman's HPV DNA status. Since some of the required model parameters were not available directly from the literature, average probabilities of progression and regression of CIN were derived using data that were not stratified by HPV status.32-33 Using an independent mathematical model, we applied the relative risk of CIN with detectable HPV and the prevalence of detectable HPV to split the overall average probabilities of progression and regression of cervical lesions for women with detectable high-risk HPV DNA and women without detectable high-risk HPV DNA. To achieve consistency with the age-specific cross-sectional data reported in the literature, the model was first used to project a series of intermediate and long-term outcomes for which there were suitable data in the absence of screening (eg, lifetime risk and age-specific cancer incidence, stage distribution of invasive disease). The model was then calibrated to the approximate distribution of detectable HPV within LSIL and HSIL. The calibration required (1) approximately 20% of acquired HPV in each monthly Markov cycle to be undetectable; (2) the probability of developing LSIL among women residing in the detectable and undetectable HPV sectors of the model to be the same; and (3) the transition of LSIL to HSIL among women residing in the undetectable HPV sector to be reduced by 80% relative to those in the detectable sector. Our model projected that approximately 5% of invasive cervical cancer would appear to be HPV-negative (ie, arising from the undetectable HPV sector).
Screening Tests
The distribution of abnormal cytological results based on cervical disease status was estimated using data from several different studies (Table 1). Data from the Columbia University Family Planning Colposcopy Clinic (1997-2001) provided probabilities of each cytological test result (ASC-US, ASC-H, LSIL, HSIL), which were conditional on the underlying disease status (normal, CIN 1, CIN 2-3, invasive cancer) (T. C. W., written communication, September 6, 2001). We then applied the relative distributions for ASC-US and ASC-H to published data that were not stratified.41-42
Estimates for the sensitivity and specificity of cervical cytology (when used for population screening) were obtained from recent published comprehensive reviews,27, 44-45 while those for repeat cervical cytology and HPV DNA testing of women with ASC-US were obtained from a formal literature review conducted for the American Society of Colposcopy and Cervical Pathology national consensus conference on management of cytological abnormalities.4-5,7-8,74
Health-Related Quality of Life
In the sensitivity analysis, the quality weights for the base case (and their plausible ranges) were 0.68 (0.60-1.00) for local cancer, 0.56 (0.40-1.00) for regional cancer, and 0.48 (0.35-1.00) for distant cancer.75 Age-specific quality weights from the Beaver Dam Health Outcomes study76 were used for noncancer states because these data were only available for women aged 40 years or older. We assumed a quality weight of 1.00 for women aged 39 years or younger.
Costs
Selected costs are shown in Table 1.9-11,27, 56-61 Direct medical costs included: screening (eg, Papanicolaou test, HPV test, treatment visit); clinician's fee(s); workup following an abnormal cytological result (eg, colposcopy) and any necessary treatment; and inpatient and/or ambulatory medical facility. Direct medical costs for screening and treatment were derived from 3 sources.27, 56-58
Cytological costs were estimated by having the model directly calculate a weighted average of normal and abnormal cervical cytological results since abnormal results require physician review and their evaluation is reimbursed at a higher rate.57 For example, the total cost for liquid-based cytology when used for general screening ranged from $71 to $107 depending on whether physician review was required. We assumed a unit HPV DNA testing cost of $48.50 based on current Centers for Medicare and Medicaid Services (formerly the Health Care Financing Administration) reimbursement rate, but this varied from $25 to $200.59 For reflex HPV testing using liquid-based cytology, this cost was added to the cost of the initial screening visit, which included the office visit, screening cytology, and a woman's time.59 For reflex HPV testing using conventional cytology, we included a $2 cost for the collection kit and handling of the specimen, but varied this cost from $1 to $10. For 2-visit HPV DNA testing, the cost of a second office visit and the additional time costs to the patient were included. The time spent undergoing screening was based on a prospective study of time costs associated with cervical cancer screening.60 Previously published data incorporating time and transportation costs were used in sensitivity analysis.9-10 To account for inflation, all costs were made constant by using dollar values from 2000 and by using the medical care component of the consumer price index.61
RESULTS
Face Validity of the Model
The model predicts age-specific prevalence of HPV infection within a plausible range of results from studies using sensitive assays to detect HPV DNA (Figure 2).62-68 Prevalence for all CIN was also found to be within the range of other published estimates, with a peak prevalence of approximately 7.1% early in the third decade.77-79 In the absence of screening, the lifetime risk of invasive cervical cancer was 3.3% and the peak annual incidence of cervical cancer was 67 per 100 000 at age 57 years, similar to values reported in the literature.11, 27-28,73, 80-81 Colposcopy referral rates were 52.5% with HPV testing, 49.7% with a single repeat cytological result of ASC-US or greater (LSIL, HSIL, or cancer), and 6.2% with a single repeat cytology result of HSIL. These results closely approximated those reported in published findings of the ASCUS/LSIL Triage Study.8
|
|
|
|
Figure 2. Prevalence of Human Papillomavirus (HPV)
The model's projected age-specific prevalence of HPV closely approximates a curve constructed by the weighted means of the prevalence reported in several clinical studies.62-68
|
|
|
Base-Case Analysis
We first assessed the discounted costs and benefits associated with different approaches to managing ASC-US given a particular clinical screening practice (Table 2). In the context of biennial screening using liquid-based cytology, the least costly strategy was to reclassify ASC-US as normal (ie, ignore a result of ASC-US), followed sequentially by HPV DNA testing, repeat cytology, and then immediate colposcopy. Compared with no screening, a strategy in which ASC-US was ignored increased discounted life expectancy by 32 days with a cost of $13 700 per year of life gained. Compared with ignoring ASC-US, reflex HPV DNA testing was associated with an incremental life expectancy benefit of 2 days with a cost of $44 400 per year of life gained. In comparison, repeat cytology was more expensive and less effective than HPV testing. Compared with HPV testing, immediate colposcopy provided an additional 2 hours in life expectancy and had an incremental cost-effectiveness ratio of $905 300 per year of life gained. Results in which life expectancy was quality-adjusted were similar (Table 2).
|
|
|
|
Table 2. Discounted Costs, Average Life Expectancy, and Incremental Cost-effectiveness of Alternative Approaches to Manage a Cytology Result of Atypical Squamous Cells Associated With Biennial Screening*
|
|
|
We repeated these analyses in the context of conventional cytology and evaluated these testing strategies: (1) reflex HPV testing using samples co-collected at the time of conventional cytology and (2) 2-visit HPV DNA testing in which a woman with an ASC-US result has to return for an HPV test. Provided that compliance with the repeat visit was 100%, the 2-visit HPV DNA testing strategy was just as effective as reflex HPV testing using co-collected samples. As estimates of compliance with the second visit decreased, the reflex HPV testing strategy using co-collected samples became more effective. As expected, under the base-case assumptions, the 2-visit HPV DNA testing was more costly than reflex HPV testing using co-collected samples. To quantify the trade-off between the cost of co-collection vs the cost of a second visit, we determined the monetary threshold at which the cost-effectiveness ratios for the 2 HPV testing strategies converge. We found that unless the cost of a repeat visit was less than $32 (including the cost of medical staff, office visit, transportation, and patient time), the co-collection strategy would be preferred.
Results were similar for analyses in which the categories of ASC-US and ASC-H were not segregated but grouped under the single traditional cytological diagnosis of ASC (lower third of Table 2). HPV DNA testing with biennial screening using conventional cytology had a cost of $24 700 per year of life gained and immediate colposcopy exceeded $400 000 per year of life gained, making it more expensive than other strategies. The life-expectancy gains associated with all strategies except immediate colposcopy were somewhat lower than in the base case; however, these differences were almost immeasurable. Stratification of ASC had a significant impact only in the context of ignoring an ASC result. Biennial screening with conventional cytology provided a 79% reduction in cancer incidence using the new stratified terminology (ASC-US and ASC-H) compared with a 75% reduction using a single cytological category of ASC.
Figure 3 shows the relationship between the discounted costs and life expectancies for all 37 potential screening strategies. This analysis assumes all strategies are available and are feasible options. The cost-effectiveness of moving from one screening strategy to a more costly alternative is represented by the difference in cost divided by the difference in life expectancy associated with the 2 strategies (this is expressed as a cost-effectiveness ratio and is shown for each nondominated strategy). Strategies on the efficiency curve dominate those to the right of the curve because they are more effective, and either cost less or have a more attractive cost-effectiveness ratio than the next best strategy.
|
|
|
|
Figure 3. Discounted Costs and Life Expectancy of Alternative Management Strategies for Screening With Liquid-Based or Conventional Cytology
YLS indicates years of life saved; ASC, atypical squamous cells; and HPV, human papillomavirus.
|
|
|
Every 5-year screening using conventional cervical cytology and ignoring an ASC-US result had a cost-effectiveness ratio of $7100 per year of life gained compared with no screening. Every 5-year screening with reflex HPV DNA testing yielded an incremental cost-effectiveness ratio of $12 100 per year of life gained compared with ignoring ASC-US. Every 5-year screening with liquid-based cytology and reflex HPV DNA testing was substantially more effective and cost $20 300 per year of life gained. The costs for the same strategy conducted per year of life gained are $59 600 for every 3 years and $174 200 for every 2 years. All strategies that relied on annual screening, regardless of the ASC-US management option, provided minimal incremental life-expectancy gains and had cost-effectiveness ratios exceeding $500 000 per year of life gained.
The inconvenience of co-collection may preclude its widespread adoption in settings where liquid-based cytology is considered too expensive for routine use. However, a longer screening interval of 3 years using the liquid-based cytology strategy of reflex HPV testing is more effective and less costly than a screening interval of every 2 years using the conventional cytology strategies of repeat cytology or immediate colposcopy.
Sensitivity Analyses
These general results were not sensitive to analyses of screening test performance, alternative management options for CIN 1, cost of the workup for an abnormal screening test result, and the costs of CIN 2-3 and cervical cancer treatment. Repeat cytology was no longer dominated when the cost of HPV DNA testing exceeded $190. The rank ordering of strategies did not change despite varying the costs of colposcopy of between $200 and $600.
When noncompliance was assumed to be random (ie, all women are equally likely to be noncompliant), lower rates of compliance resulted in lower costs and more attractive cost-effectiveness ratios. For example, when compliance was decreased to 60% for each return visit in the strategies of repeat cytology, reflex HPV testing no longer dominated repeat cytology because the cost savings associated with losing patients to follow-up was relatively greater than the loss in clinical benefits. When noncompliance was assumed to be systematic (ie, women at greater risk for cervical cancer are more likely to be noncompliant), this counterintuitive result was somewhat blunted—lower rates of compliance were still associated with lower costs, but the loss in clinical benefits resulting from women at high risk being lost to follow-up were greater than when women were at average risk. In both situations, however, HPV DNA testing remained more effective than repeat cytology and had an attractive cost-effectiveness ratio of between $19 000 and $29 000 per year of life gained compared with repeat cytology strategy when using biennial screening with liquid cytology. This pattern was similar for noncompliance with screening, follow-up visits, and colposcopy.
COMMENT
Managing the approximately 2 million US women with equivocal cervical cytological results each year is a significant clinical and public health problem.82 This year a national consensus conference was held to develop evidence-based guidelines for the management of women with cervical cytological abnormalities.74 To provide information for the guideline process, we conducted a comprehensive cost-effectiveness analysis of alternative strategies for women with ASC.
We first assessed the best option for ASC-US management given a particular clinical screening practice, since all possible strategies evaluated in this article may not be universally accessible and feasible. Our results indicate that a policy of ignoring a cytological result of ASC-US reduces the effectiveness of cervical cancer screening compared with HPV testing, repeat cytology, or immediate colposcopy, especially when longer screening intervals or less sensitive screening methods are used. There are extremely small differences between the 3 ASC-US management strategies in terms of cancer incidence reduction, although under all conditions repeat cervical cytology is somewhat less effective than either HPV DNA testing or immediate colposcopy. In contrast, the costs associated with ASC-US management strategies differed substantially. Immediate colposcopy was always more costly than either repeat cervical cytology or HPV DNA testing. Regardless of the clinical scenario evaluated, referral of all women with ASC-US for colposcopy had incremental cost-effectiveness ratios exceeding $200 000 per year of life gained compared with HPV DNA testing. Reflex HPV DNA testing was always less costly than repeat cytology, in part because it eliminates the need for a repeat clinical examination to obtain a cervical specimen in the case of ASC-US and reduces the number of colposcopic examinations by 40% to 60% compared with immediate colposcopy. Our results were not affected by reasonable changes in screening costs, performance of HPV testing and cytology, and time costs. Our base case incorporated the new 2001 Bethesda System that subcategorizes ASC into ASC-US and ASC-H. Recent clinical practice guidelines recommend that since women with ASC-H are at increased risk for having CIN 2-3, they should have immediate colposcopy. However, our analyses indicate that subcategorizing ASC makes little difference in terms of clinical benefits, provided some follow-up of ASC-US occurs.
We then assessed the most efficient screening options by considering alternative strategies to manage ASC-US while simultaneously varying all possible screening frequencies and type of cytological tests. This was done from a broad health policy perspective and assuming all strategies are equally available and feasible. Similar to others, we found that all strategies that rely on annual screening, regardless of the ASC-US management option, provide minimal incremental life-expectancy gains compared with less frequent screening strategies and have extremely high and unattractive cost-effectiveness ratios (>$500 000 per year of life gained).27-28,73, 83-86 A biennial screening program using liquid-based cytology combined with reflex HPV DNA testing for women with ASC-US is more effective and less costly than annual conventional cytology coupled with either repeat cervical cytology or colposcopy for women with ASC-US. However, the cost-effectiveness ratio of this strategy ($174 200 per year of life gained) is higher than many clinical preventive interventions that have been adopted in the United States.87 There is no consensus that defines the cost per QALY and represents an acceptable value for money, however, cost-effectiveness ratios are often placed in context by comparisons with interventions that are widely mandated, such as hemodialysis for end-stage renal disease of between $60 000 and $128 000 per year of life gained.88 In our model, screening performed every 3 years, using liquid-based cytology coupled with reflex HPV DNA testing, has an incremental cost-effectiveness ratio of approximately $60 000 per year of life gained over screening performed every 5 years and would be considered a cost-effective intervention. It is important to emphasize, however, that in the context of current cervical cancer screening practices in the United States, shifting women currently being screened annually with conventional cytology coupled with repeated cytology for an ASC-US result to biennial liquid-based cytology and reflex HPV DNA testing would save more than $15 billion over the lifetime of a typical cohort of 18-year-old to 24-year-old women.89
Our analysis has a number of limitations. There is considerable uncertainty with respect to the longitudinal nature of HPV infection and our results may be further refined as better data become available. There is also considerable variability with respect to the distribution of cytological results in women with CIN 2-3, although our results did not change significantly despite using parameters from 3 different clinical studies.40-42 Unknown factors that contribute to population heterogeneity and possible cofactors that contribute to an individual's risk of disease progression could not be modeled,90 although we did try to explore the implications of certain heterogeneous behaviors, such as those reflecting noncompliance.91
This analysis provides important insights for both policy makers developing management guidelines for women with ASC results, as well as for clinicians caring for these women. In interpreting these findings, it is important to recognize that not only are women's relative preferences for a potential outcome important when deciding the best option in a given clinical setting, but other factors must also be considered.92 For example, there are settings in which liquid-based cytology is already the standard of care, and others in which conventional cytology is the only option. Some settings will find co-collection suited to their daily operational systems and others will not. However, many of our key findings were robust in a variety of settings. First, in the context of current cervical cancer screening practice in the United States, follow-up for ASC-US provides clinical benefits at a reasonable cost. Second, under the conditions of our base case, reflex HPV DNA testing appears to provide clinical benefits similar to those of immediate colposcopy for women with ASC-US, but is less costly. Finally, a triennial or biennial cervical cancer screening program incorporating liquid-based cytology and reflex HPV DNA testing is more effective and less costly than annual screening with conventional cytology and repeat cytology for women with ASC. Thus, the aggregate health economic costs saved by adopting such a policy would be enormous.
AUTHOR INFORMATION
Author Contributions: Study concept and design: Kim, Wright, Goldie.
Acquisition of data: Wright.
Analysis and interpretation of data: Kim, Wright, Goldie.
Drafting of the manuscript: Kim, Wright, Goldie.
Critical revision of the manuscript for important intellectual content: Kim, Wright, Goldie.
Statistical expertise: Kim, Goldie.
Administrative, technical, or material support: Goldie.
Study supervision: Goldie.
Financial Disclosure: Dr Wright was the principal investigator for clinical trials investigating HPV DNA testing and liquid-based cytology funded by Digene Corp and Cytyc Corp via formal grants to Columbia University. He currently serves on the speaker's bureaus of Cytyc Corp and Tripath Inc, which make liquid-based cytology test kits.
Corresponding Author and Reprints: Sue J. Goldie, MD, MPH, Department of Health Policy and Management, Harvard Center for Risk Analysis, 718 Huntington Ave, Second Floor, Boston, MA 02115 (e-mail: sgoldie{at}hsph.harvard.edu).
Author Affiliations: Department of Health Policy and Management, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Mass (Ms Kim and Dr Goldie) and the Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY (Dr Wright).
REFERENCES
| |
1. Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med. 2000;124:672-681.
ISI
| PUBMED
2. Kurman RJ, Henson DE, Herbst AL, et al. Interim guidelines for management of abnormal cervical cytology. JAMA. 1994;271:1866-1869.
FREE FULL TEXT
3. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? Obstet Gynecol. 1998;91:973-976.
FULL TEXT
|
ISI
| PUBMED
4. Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol. 1995;85:202-210.
FULL TEXT
|
ISI
| PUBMED
5. Ferris DG, Wright TC Jr, Litaker MS, et al. Triage of women with ASCUS and LSIL on Pap smear reports. J Fam Pract. 1998;46:125-134.
ISI
| PUBMED
6. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia. JAMA. 1999;281:1605-1610.
FREE FULL TEXT
7. Wright TC Jr, Lorincz A, Ferris DG, et al. Reflex HPV DNA testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol. 1998;178:962-966.
FULL TEXT
|
ISI
| PUBMED
8. Solomon D, Schiffman M, Tarrone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. J Natl Cancer Inst. 2001;93:293-299.
FREE FULL TEXT
9. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med. 1999;130:97-107.
FREE FULL TEXT
10. Goldie SJ, Freedberg KA, Weinstein MC, et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med. 2001;111:140-149.
FULL TEXT
|
ISI
| PUBMED
11. Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings. JAMA. 2001;285:3107-3115.
FREE FULL TEXT
12. Wright TC, Ferenczy AF, Kurman RJ. Precancerous lesions of the cervix. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 4th ed. New York, NY: Springer-Verlag; 1994:229-278.
13. Surveillance, Epidemiology, End Results (SEER) Cancer Statistics Review, 1973-1994. Bethesda, Md: National Cancer Institute; 1997. Available at: http://www-seer.ims.nci.nih.gov. Accessed August 1, 2001.
14. Schiffman M. New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 1995;87:1345-1347.
FREE FULL TEXT
15. Koutsky LA, Kiviat NB. Genital human papillomavirus. In: Holmes K, Mardh P, Sparling P, et al, eds. Sexually Transmitted Disease. 3rd ed. New York, NY: McGraw-Hill; 1999:347-360.
16. Schlecht NF, Kulaga S, Robitaille J, et al. Persistant human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106-3114.
FREE FULL TEXT
17. Solomon D, Davey DD, Moriarty A, et al. Terminology for Reporting the Results of Cervical Cytology. Bethesda, Md: National Cancer Institute; 2001. Available at: http://bethesda2001.cancer.gov/terminology.html. Accessed February 1, 2002.
18. Sherman ME, Tabbara SO, Scott DR, et al. ‘ASCUS, rule out HSIL.'. Mod Pathol. 1999;12:335-342.
ISI
| PUBMED
19. Malik SN, Wilkinson EJ, Drew PA, et al. Do qualifiers of ASCUS distinguish between low- and high-risk patients? Acta Cytol. 1999;43:376-380.
ISI
| PUBMED
20. Gold MR, Siegel JE, ed, Russel LB, ed, Weinstein MC, ed. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
21. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169:235-240.
ISI
| PUBMED
22. Ho GYF, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
FREE FULL TEXT
23. Liu T, Seng-jaw S, Alvarez R, Butterworth C Jr. A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression. Cancer Epidemiol Biomarkers Prev. 1995;4:373-380.
ABSTRACT
24. Cuzick J. Human papillomavirus testing for cerical screening. Health Technol Assess. 1999;3:14.
PUBMED
25. Lawson HW, Lee NC, Thames SF, et al. Cervical cancer screening among low-income women. Obstet Gynecol. 1998;92:745-752.
FULL TEXT
|
ISI
| PUBMED
26. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343-1349.
FREE FULL TEXT
27. McCrory D, Mather D, Bastain L, et al. Evaluation of Cervical Cytology: Evidence Report/Technology Assessment No.5. Rockville, Md: Agency for Health Care Policy and Research; 1999. AHCPR publication 99-E010.
28. Myers E, McCrory D, Nanda K, Matchar D. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158-1171.
FREE FULL TEXT
29. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer. 1996;69:364-368.
FULL TEXT
|
ISI
| PUBMED
30. Syrjanen K, Kataja V, Yliskoski M, et al. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol. 1992;79:675-682.
ISI
| PUBMED
31. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87:1365-1371.
FREE FULL TEXT
32. Ostor AG. Natural history of cervical intraepithelial neoplasia. Int J Gynecol Pathol. 1993;12:186-192.
ISI
| PUBMED
33. Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions. Obstet Gynecol. 1998;92(4 pt 2):727-735.
34. Ho GY, Kadish AS, Burk RD, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer. 1998;78:281-285.
FULL TEXT
|
ISI
| PUBMED
35. Hopman EH, Rozendaal L, Voorhorst FJ, et al. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG. 2000;107:600-604.
FULL TEXT
| PUBMED
36. Rozendaal L, Walboomers JM, van der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 1996;68:766-769.
FULL TEXT
|
ISI
| PUBMED
37. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA. 2000;283:1031-1037.
FREE FULL TEXT
38. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272-1278.
ABSTRACT
39. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354:20-25.
FULL TEXT
|
ISI
| PUBMED
40. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease. Int J Cancer. 1995;61:306-311.
ISI
| PUBMED
41. Lonky NM, Sadeghi M, Tsadik GW, Petitti D. The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytologic results. Am J Obstet Gynecol. 1999;181:560-566.
FULL TEXT
|
ISI
| PUBMED
42. Jones BA, Novis DA. Follow-up of abnormal gynecologic cytology. Arch Pathol Lab Med. 2000;124:665-671.
ISI
| PUBMED
43. Statistical Abstract of the United States: Consumer Price Index: All Urban Consumers. Washington, DC: National Center for Health Statistics; 2001. Available at: http://www.cdc.gov/nchswww/data/gm291_1.pdf. Accessed September 1, 2001.
44. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680-689.
FREE FULL TEXT
45. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-819.
FREE FULL TEXT
46. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol. 2000;95:821-827.
FULL TEXT
|
ISI
| PUBMED
47. Ferris DG, Wright TC Jr, Litaker MS, et al. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract. 1998;46:136-141.
ISI
| PUBMED
48. Lin CT, Tseng CJ, Lai CH, et al. High-risk HPV DNA detection by Hybrid Capture II. J Reprod Med. 2000;45:345-350.
ISI
| PUBMED
49. Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM Jr. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on Papanicolaou smears. Obstet Gynecol. 2000;96:410-416.
FULL TEXT
|
ISI
| PUBMED
50. Hutchinson ML, Zahniser DJ, Sherman ME, et al. Utility of liquid-based cytology for cervical carcinoma screening. Cancer. 1999;87:48-55.
FULL TEXT
|
ISI
| PUBMED
51. Diaz-Rosario LA, Kabawat SE. Performance of a fluid-based, thin-layer Papanicolaou smear method in the clinical setting of an independent laboratory and an outpatient screening population in New England. Arch Pathol Lab Med. 1999;123:817-821.
ISI
| PUBMED
52. Ashfaq R, Gibbons D, Vela C, et al. ThinPrep Pap test. Acta Cytol. 1999;43:81-85.
ISI
| PUBMED
53. Bai H, Sung CJ, Steinhoff MM. ThinPrep Pap test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol. 2000;23:19-22.
FULL TEXT
|
ISI
| PUBMED
54. Quddus MR, Sung CJ, Steinhoff MM, et al. Atypical squamous metaplastic cells. Cancer. 2001;93:16-22.
FULL TEXT
|
ISI
| PUBMED
55. Franco EL, Ferenczy A. Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage of women with cervical cytologic abnormalities. Am J Obstet Gynecol. 1999;181:382-386.
ISI
| PUBMED
56. Helms LJ, Melnikow J. Determining costs of health care services for cost-effectiveness analyses. Med Care. 1999;37:652-661.
FULL TEXT
|
ISI
| PUBMED
57. National physician fee schedule relative value file: Medicare fee schedule. Available at: http://www.hcfa.gov/medicare/pfsmain.htm. Accessed October 1, 2001.
58. Muller C, Mandelblatt J, Schechter C. The Costs and Effectiveness of Screening for Cervical Cancer in Elderly Women. Washington, DC: Office of Technology Assessment; 1990.
59. 2001 clinical diagnostic laboratory fee schedule: public use file. Available at: http://www.hcfa.gov/stats/pufiles.htm#labfee. Accessed October 1, 2001.
60. Shireman TI, Tsevat J, Goldie SJ. Time costs associated with cervical cancer screening. Int J Technol Assess Health Care. 2001;17:146-152.
FULL TEXT
|
ISI
| PUBMED
61. US Bureau of Labor Statistics. Statistical Abstract of the United States. Washington, DC: US Government Printing Office; 2001. Publication 96-186.
62. Moscicki AB. Human papillomavirus infection in adolescents. Pediatr Clin North Am. 1999;46:783-807.
FULL TEXT
|
ISI
| PUBMED
63. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis. 1996;23:333-341.
ISI
| PUBMED
64. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis. 1993;20:274-278.
ISI
| PUBMED
65. Melkert PJ, Hopman E, van den Brule J, et al. Prevalence of HPV in cytomorphlogically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993;53:919-923.
ISI
| PUBMED
66. Burk RD, Ho GYF, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996;174:679-689.
ISI
| PUBMED
67. Kotloff KL, Wasserman SS, Russ K, et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis. 1998;25:243-250.
ISI
| PUBMED
68. Sellors JW. Cervical cancer prevention for all Canadians. Can Fam Physician. 1999;45:245-247, 252-254.
ISI
| PUBMED
69. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284.
FULL TEXT
|
ISI
| PUBMED
70. Franco E, Villa L, Sobrinho J, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180:1415-1423.
FULL TEXT
|
ISI
| PUBMED
71. Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes Control. 1992;3:125-136.
FULL TEXT
|
ISI
| PUBMED
72. Ponten J, Adami HO, Bergstrom R, et al. Strategies for global control of cervical cancer. Int J Cancer. 1995;60:1-26.
ISI
| PUBMED
73. Sherlaw-Johnson C, Gallivan S, Jenkins D. Evaluating cervical cancer screening programmes for developing countries. Int J Cancer. 1997;72:210-216.
FULL TEXT
|
ISI
| PUBMED
74. Wright TC Jr, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
FREE FULL TEXT
75. Gold M, Franks P, McCoy K, Fryback DG. Toward consistency in cost-utility analyses. Med Care. 1998;36:778-792.
FULL TEXT
|
ISI
| PUBMED
76. Fryback D, Dasbach E, Klein R, et al. Initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
FREE FULL TEXT
77. Sawaya GF, Kerlikowske K, Lee NC, Gildengorin G, Washington AE. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol. 2000;96:219-223.
FULL TEXT
|
ISI
| PUBMED
78. Results from the National Breast and Cervical Cancer Early Detection Program, October 31, 1991-September 30, 1993. MMWR Morb Mortal Wkly Rep. 1994;43:530-534.
PUBMED
79. Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics. 1999;103:539-545.
FREE FULL TEXT
80. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer. 1997;71:159-165.
FULL TEXT
|
ISI
| PUBMED
81. Pettersson F, Bjorkholm E, Naslund I. Evaluation of screening for cervical cancer in Sweden. Int J Epidemiol. 1985;14:521-527.
FREE FULL TEXT
82. Cox JT, Wilkinson EJ, Lonky N, et al. Management guidelines for the follow-up of atypical squamous cells of undetermined significance (ASCUS). J Lower Genital Tract. 2000;4:99-105.
83. Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA. 1999;281:347-353.
FREE FULL TEXT
84. Eddy DM. Screening for cervical cancer. Ann Intern Med. 1990;113:214-226.
FREE FULL TEXT
85. Fahs MC, Plichta SB, Mandelblatt JS. Cost-effective policies for cervical cancer screening. Pharmacoeconomics. 1996;9:211-230.
ISI
| PUBMED
86. Fahs MC, Mandelblatt J, Schechter C, Muller C. Cost-effectiveness of cervical cancer screening for the elderly. Ann Intern Med. 1992;117:520-527.
FULL TEXT
|
ISI
| PUBMED
87. Graham JD, Corso PS, Morris JM, et al. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health. 1998;19:125-152.
FULL TEXT
|
ISI
| PUBMED
88. Weinstein MC. High-priced technology can be good value for money. Ann Intern Med. 1999;130:857-858.
FREE FULL TEXT
89. Population Estimates Program. Washington, DC: US Census Bureau; 2000. Available at: http://www.census.gov/population/estimates/nation/intfile2-1.txt. Accessed August 24, 2001.
90. Kuntz KM, Goldie SJ. Defining the effects of population heterogeneity in Markov models. Med Decis Making. 2000;20:484.
91. Goldie SJ, Kuntz KM. Modeling compliance in cost-effectiveness analyses of screening programs. Med Decis Making. 2001;20:529.
92. Barry M. Health decision aids to facilitate shared decision making in office practice. Ann Intern Med. 2002;136:127-135.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTER
Testing for Human Papillomavirus in Women With Abnormal Pap Smear Results
Kirsten J. McCaffery, Jo Waller, Sue Forrest, Jane Wardle, George F. Sawaya, Karen Smith-McCune, Thomas C. Wright, Jr, J. Thomas Cox, L. Stewart Massad, Leo B. Twiggs, and Edward J. Wilkinson
JAMA. 2002;288(11):1350.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer
Jeanne S. Mandelblatt, William F. Lawrence, Sharita Mizell Womack, Denise Jacobson, Bin Yi, Yi-ting Hwang, Karen Gold, James Barter, and Keerti Shah
JAMA. 2002;287(18):2372-2381.
ABSTRACT
| FULL TEXT
Visualizing Cost-effectiveness Analysis
David H. Mark
JAMA. 2002;287(18):2428-2429.
EXTRACT
| FULL TEXT
May 8, 2002
JAMA. 2002;287(18):2437-2438.
EXTRACT
| FULL TEXT
2001 Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities
Thomas C. Wright, Jr, J. Thomas Cox, L. Stewart Massad, Leo B. Twiggs, Edward J. Wilkinson, and for the 2001 ASCCP-Sponsored Consensus Conference
JAMA. 2002;287(16):2120-2129.
ABSTRACT
| FULL TEXT
Persistent Human Papillomavirus Infection as a Predictor of Cervical Intraepithelial Neoplasia
Nicolas F. Schlecht, Sophie Kulaga, Juliette Robitaille, Silvaneide Ferreira, Monica Santos, Romulo A. Miyamura, Eliane Duarte-Franco, Thomas E. Rohan, Alex Ferenczy, Luisa L. Villa, and Eduardo L. Franco
JAMA. 2001;286(24):3106-3114.
ABSTRACT
| FULL TEXT
Policy Analysis of Cervical Cancer Screening Strategies in Low-Resource Settings: Clinical Benefits and Cost-effectiveness
Sue J. Goldie, Louise Kuhn, Lynette Denny, Amy Pollack, and Thomas C. Wright
JAMA. 2001;285(24):3107-3115.
ABSTRACT
| FULL TEXT
Incidence of Cervical Squamous Intraepithelial Lesions in HIV-Infected Women
Tedd V. Ellerbrock, Mary Ann Chiasson, Timothy J. Bush, Xiao-Wei Sun, Dorothy Sawo, Karen Brudney, and Thomas C. Wright, Jr
JAMA. 2000;283(8):1031-1037.
ABSTRACT
| FULL TEXT
Cost-effectiveness of 3 Methods to Enhance the Sensitivity of Papanicolaou Testing
Adalsteinn D. Brown and Alan M. Garber
JAMA. 1999;281(4):347-353.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination
Goldhaber-Fiebert et al.
JNCI J Natl Cancer Inst 2008;100:308-320.
ABSTRACT
| FULL TEXT
Abnormal Outcomes Following Cervical Cancer Screening: Event Duration and Health Utility Loss
Insinga et al.
Med Decis Making 2007;27:414-422.
ABSTRACT
Multiparameter Calibration of a Natural History Model of Cervical Cancer
Kim et al.
Am J Epidemiol 2007;166:137-150.
ABSTRACT
| FULL TEXT
Disclosure Of Medical Injury To Patients: An Improbable Risk Management Strategy
Studdert et al.
Health Aff (Millwood) 2007;26:215-226.
ABSTRACT
| FULL TEXT
The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany
Siebert et al.
Eur J Public Health 2006;16:185-192.
ABSTRACT
| FULL TEXT
Epidemiology and Natural History of Genital Human Papillomavirus Infection
Weaver
JAOA: Journal of the American Osteopathic Association 2006;106:S2-S8.
ABSTRACT
| FULL TEXT
Human Papillomavirus Triage of Atypical Squamous Cells of Undetermined Significance: Cost-Effective, But At What Cost?
Melnikow and Birch
JNCI J Natl Cancer Inst 2006;98:82-83.
FULL TEXT
Cost-Effectiveness Analysis Based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS)
Kulasingam et al.
JNCI J Natl Cancer Inst 2006;98:92-100.
ABSTRACT
| FULL TEXT
Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies
Legood et al.
BMJ 2006;332:79-85.
ABSTRACT
| FULL TEXT
A 21-Year-Old Woman With Atypical Squamous Cells of Undetermined Significance
Sawaya
JAMA 2005;294:2210-2218.
FULL TEXT
Acceptability of human papillomavirus self testing in female adolescents
Kahn et al.
Sex. Transm. Infect. 2005;81:408-414.
ABSTRACT
| FULL TEXT
Colposcopy: An Evidence-Based Update
Dresang
J Am Board Fam Med 2005;18:383-392.
ABSTRACT
| FULL TEXT
Screening for Cervical Cancer and Initial Treatment of Patients With Abnormal Results From Papanicolaou Testing
Bundrick et al.
Mayo Clin Proc. 2005;80:1063-1068.
ABSTRACT
Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy
Kim et al.
JNCI J Natl Cancer Inst 2005;97:888-895.
ABSTRACT
| FULL TEXT
HPV Communication: Review of Existing Research and Recommendations for Patient Education
Anhang et al.
CA Cancer J Clin 2004;54:248-259.
ABSTRACT
| FULL TEXT
Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
Goldie et al.
JNCI J Natl Cancer Inst 2004;96:604-615.
ABSTRACT
| FULL TEXT
Virologic Versus Cytologic Triage of Women With Equivocal Pap Smears: A Meta-analysis of the Accuracy To Detect High-Grade Intraepithelial Neoplasia
Arbyn et al.
JNCI J Natl Cancer Inst 2004;96:280-293.
ABSTRACT
| FULL TEXT
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs
Kulasingam and Myers
JAMA 2003;290:781-789.
ABSTRACT
| FULL TEXT
Chapter 14: Role of Triage Testing in Cervical Cancer Screening
Solomon
J Natl Cancer Inst Monogr 2003;2003:97-101.
ABSTRACT
| FULL TEXT
Chapter 15: Public Health Policy and Cost-Effectiveness Analysis
Goldie
J Natl Cancer Inst Monogr 2003;2003:102-110.
ABSTRACT
| FULL TEXT
Cervical Cancer Screening: From the Papanicolaou Smear to the Vaccine Era
Crum et al.
JCO 2003;21:224s-230.
ABSTRACT
| FULL TEXT
Histopathologic Extent of Cervical Intraepithelial Neoplasia 3 Lesions in the Atypical Squamous Cells of Undetermined Significance Low-grade Squamous Intraepithelial Lesion Triage Study: Implications for Subject Safety and Lead-time Bias
Sherman et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:372-379.
ABSTRACT
| FULL TEXT
Human Papillomavirus and Cervical Cancer
Burd
Clin. Microbiol. Rev. 2003;16:1-17.
ABSTRACT
| FULL TEXT
American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer
Saslow et al.
CA Cancer J Clin 2002;52:342-362.
ABSTRACT
| FULL TEXT
Testing for Human Papillomavirus in Women With Abnormal Pap Smear Results
McCaffery et al.
JAMA 2002;288:1350-1350.
FULL TEXT
Appropriate Screening for Cervical Cancer
Journal Watch Dermatology 2002;2002:11-11.
FULL TEXT
Appropriate Screening for Cervical Cancer
JWatch General 2002;2002:3-3.
FULL TEXT
Visualizing Cost-effectiveness Analysis
Mark
JAMA 2002;287:2428-2429.
FULL TEXT
|
